Everolimus is a type of drug developed by Novartis Pharmaceuticals and approved by the US Food and Drug Administration in 2015 for the shrinking of tumors. Everolimus is an mTOR inhibitor, which is a class of drugs that block the mTOR signaling pathway, which is a key part of certain cancer cells’ motivations to grow and divide. By blocking the mTOR pathway, Everolimus has been shown to have the potential to shrink certain tumors and prevent their growth.
Results from clinical trials
In clinical trials, Everolimus has been found to be an effective agent for shrinking tumors in certain types of soft tissue sarcoma and kidney cancer. In a clinical trial for soft tissue sarcoma, Everolimus was found to shrink tumors in 14 of the 40 patients that participated in the study. Of those 14 patients, four had a complete response, meaning that all evidence of the tumor had disappeared. In the kidney cancer trials, Everolimus was found to be able to shrink tumors in 8 out of 29 patients and one of these patients had a complete response.
Effective mode of action
In addition to visceral tumors, Everolimus has been shown to have the potential to shrink tumors in the brain. A study conducted in 2016 found that when combined with radiation therapy, Everolimus was able to help shrink the size of tumors in 10 out of 11 patients. This study only tested patients with brain metastases who had already been treated with conventional methods, so further study is needed to determine the effectiveness of Everolimus for other types of brain tumors.
While Everolimus has been found to be an effective agent for shrinking tumors, there are potential side effects that patients should be aware of. These side effects may include a decrease in white blood cell count, mouth sores, nausea, diarrhea, fatigue, and rash. Patients using Everolimus may need to have their blood work and other tests monitored regularly to spot any issues early on and to ensure that the Everolimus is safe and effective.
An effective agent
Overall, Everolimus has shown to be an effective agent for shrinking tumors in certain types of sarcoma, kidney cancer, and brain cancers. If a patient has a tumor that could benefit from mTOR inhibition, it is recommended that they consult their doctor and consider the potential benefits and side effects of taking Everolimus. With proper monitoring, Everolimus has the potential to shrink tumors and potentially prevent their growth and spread.
Insight into it
Everolimus 5mg is an anti-cancer drug used to treat a variety of cancers, including kidney, breast, and lung cancer. It is a targeted therapy, which means it is specifically designed to target cancer cells and the proteins that regulate their growth and spread. This makes it useful for treating cancers that have become resistant to other types of treatments. The drug is available in tablet form, usually taken once a day and swallowed with a glass of water.
Dose of its action
Everolimus works by inhibiting the activity of a molecule called mTOR (mechanistic target of rapamycin). mTOR is responsible for controlling a number of different processes in cells involved in the growth and spread of cancer. By blocking the activity of this molecule, Everolimus stops these processes from happening, ultimately stopping cancer from growing and spreading further.
Cost of Everolimus 5mg tablets
The cost of Everolimus 5mg Tablet is variable and depends on several factors, such as where they are purchased, insurance covers, etc. The price of one 30-tablet bottle is around $700. However, it can vary depending on the pharmacy and the patient’s health insurance. Additionally, generic versions of Everolimus are available and generally cost less. Be sure to check with your healthcare provider to see which version of the drug is right for you and to see if you’re eligible for any discounts or additional savings.
Effects to be taken with care
In addition to the financial cost, Everolimus also carries a risk of side effects, especially in people with kidney or liver disease. Common side effects can include vomiting, diarrhea, anemia, abnormal blood test results, and abnormal liver function tests. If any of these side effects occur, it is important to contact your healthcare provider. Rare but serious side effects, such as serious allergic reactions, have been reported in some cases.
Q:- This drug is developed by which company?
Ans:- Everolimus is a type of drug developed by Novartis Pharmaceuticals
Q:- What is its mode of action?
Ans:- Everolimus is an mTOR inhibitor, which is a class of drugs that block the mTOR signaling pathway, which is a key part of certain cancer cells’ motivations to grow and divide
Q:- What is it mainly used to treat?
Ans:- Everolimus 5mg is an anti-cancer drug used to treat a variety of cancers, including kidney, breast, and lung cancer